Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.

BACKGROUND Infection with human papillomavirus (HPV) 16 or HPV18 elicits an antibody response, but whether the elicited antibodies protect women against subsequent infection by a homologous HPV type compared with seronegative women is unknown. METHODS Study participants were women aged 18-25 years at enrollment in the control group of the ongoing National Cancer Institute-sponsored, community-based, randomized HPV16/18 Costa Rica Vaccine Trial. At enrollment, 2813 participants were negative for cervical HPV16 DNA and 2950 for HPV18 DNA. Women were interviewed regarding sociodemographic data and medical and health history. Medical and pelvic examinations were conducted for all consenting sexually experienced women. Serum samples taken at enrollment were tested for total HPV16/18 antibodies with a polyclonal enzyme-linked immunosorbent assay, and cervical specimens were tested for type-specific HPV DNA over 4 years of follow-up. Using Poisson regression, we compared rate ratios of newly detected cervical HPV16 or HPV18 infection among homologous HPV-seropositive and HPV-seronegative women, adjusting for age, education, marital status, lifetime number of sexual partners, and smoking. RESULTS There were 231 newly detected HPV16 infections during 5886 person-years among HPV16-seronegative women compared with 12 newly detected HPV16 infections during 581 person-years among HPV16-seropositive women with the highest HPV16 sero-levels. There were 136 newly detected HPV18 infections during 6352 person-years among HPV18-seronegative women compared with six new infections detected during 675 person-years among HPV18 seropositives with the highest sero-levels. After controlling for risk factors associated with newly detected HPV infection, having high HPV16 antibody titer at enrollment was associated with a reduced risk of subsequent HPV16 infection (women in the highest tertile of HPV16 antibody titers, adjusted rate ratio = 0.50, 95% confidence interval = 0.26 to 0.86 vs HPV16-seronegative women). Similarly, having high HPV18 antibody titer at enrollment was associated with a reduced risk of subsequent HPV18 infection (women in the highest tertile of HPV18 antibody titers, adjusted rate ratio = 0.36, 95% confidence interval = 0.14 to 0.76 vs HPV18-seronegative women). CONCLUSION In this study population, having high antibody levels against HPV16 and HPV18 following natural infection was associated with reduced risk of subsequent HPV16 and HPV18 infections.

[1]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[2]  D. Lowy,et al.  Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. , 2009, The Journal of infectious diseases.

[3]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[4]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.

[5]  L. Pinto,et al.  Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine , 2008, Human vaccines.

[6]  Diane Solomon,et al.  Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. , 2008, Vaccine.

[7]  F. X. Bosch,et al.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.

[8]  A. Hildesheim,et al.  Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. , 2008, Vaccine.

[9]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[10]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[11]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[12]  Edson Duarte Moreira Júnior,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.

[13]  W. Quint,et al.  Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.

[14]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[15]  J. Hogan,et al.  Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[17]  M. Sherman,et al.  Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica , 2004, British Journal of Cancer.

[18]  M. Sherman,et al.  Short Communication Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection: Results from a Population-Based Study in Costa Rica , 2004 .

[19]  N. Kiviat,et al.  Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. , 2003, American journal of epidemiology.

[20]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[21]  R. Burk,et al.  Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. , 2002, The Journal of infectious diseases.

[22]  R. Karron,et al.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.

[23]  Wim Quint,et al.  Development and Clinical Evaluation of a Highly Sensitive PCR-Reverse Hybridization Line Probe Assay for Detection and Identification of Anogenital Human Papillomavirus , 1999, Journal of Clinical Microbiology.

[24]  W. Quint,et al.  Technical Advance Novel Short-Fragment PCR Assay for Highly Sensitive Broad-Spectrum Detection of Anogenital Human Papillomaviruses , 1998 .

[25]  D. Lowy,et al.  Papillomavirus-like particles and HPV vaccine development. , 1996, Seminars in cancer biology.

[26]  Office of Research on Women's Health National Institutes of Health , 1996 .

[27]  R. Schlegel,et al.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Lowy,et al.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection , 1995, Journal of virology.